NEXGEL, INC.
Close on Oct 19, 2026
- Market cap
- $52.28M
- P/E (TTM)
- –
- Dividend yield
- –
About Nexgel
Surgical & Medical Instruments & Apparatus, SIC 3841
NexGel, Inc. manufactures custom high-water-content polymer hydrogels using electron-beam cross-linking technology for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It operates as a contract manufacturer supplying bulk gels to third parties, offers custom and white-label manufacturing, and sells branded consumer products. Its consumer brand portfolio includes Medagel over-the-counter remedies, Kenkoderm skincare for psoriasis, and Silly George beauty products. In addition, the business develops medical devices designed to reduce skin irritation, such as its NEXDrape surgical drape and NEXDerm adhesive tape, intending to license them to corporate partners rather than commercializing them directly.
The company operates a 13,500-square-foot hydrogel manufacturing facility and subleases approximately 6,200 square feet of office and manufacturing space in Granbury, Texas, through a fifty-percent-owned joint venture, CG Converting and Packaging, LLC. It markets its products primarily in the United States and internationally through contract manufacturing clients. Its principal executive offices are located in Langhorne, Pennsylvania.
Summary of the business section of Nexgel's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NEXGEL, INC.
- Founded
- 2009
- Headquarters
- Langhorne, PA
- Address
- 2150 Cabot Blvd West,, Suite B 19047
- Phone
- (215) 702-8550
- Employees
- 19, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Turner, Stone & Company, L.L.P., Dallas, Texas
Stock & identifiers
- Ticker
- NXGL
- Other tickers
- NXGLW
- Exchange
- Nasdaq
- IPO date
- Dec 22, 2021
- Shares outstanding
- 10M, Aug 14, 2026
- Public float
- $11.03M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Oct 12, 2026; 1-for-35 reverse, Nov 29, 2021
- SEC CIK
- 1468929
- CUSIP
- 65344E115
- ISIN
- US65344E1156
- EIN
- 26-4042544
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adam R. Levy | Chief Executive Officer, Director | 322,692 |
| Ian Howard Blackman | Chief Financial Officer | – |
| Joseph F. McGuire | Chief Financial Officer | 4,082 |
| Adam E. Drapczuk III | Chief Financial Officer | 99,994 |
| Scott Robert Henry | Director | 113,356 |
| Brian Joseph Kieser | Director | – |
| Kevin McClain Harris | Director | – |
| Steven Ciardiello | Director | 21,739 |
| John Nachum Stein | Director | 471,456 |
| Jerome B. Zeldis | Director | 106,664 |
| steven mark glassman | Director | 156,655 |
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 19 full-time employees.”
Corporate history
Events identified from SEC filings